🔴 GT Biopharma is trading 12% down today after Nasdaq disclosed 1-for-25 reverse split

GT Biopharma is trading 12% down now at $0.22 after Nasdaq disclosed a 1-for-25 reverse stock split effective September 8, 2026.

• The action will consolidate every 25 shares into one and introduce a new CUSIP, highlighting the company’s ongoing listing-compliance and capital-structure pressures.
• The decline follows a 10.81% drop on September 3, extending recent weakness ahead of the reverse-split effective date.
• The U.S. market is moderately weaker, but Nasdaq disclosure is the primary catalyst.